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The identification and management of virological failure (VF) 
in people living with HIV (PLWH) is a cornerstone of successful 
HIV care. Fortunately viral load (VL) monitoring of individuals on 
therapy, recommended by the World Health Organization,[1] has 
expanded vastly in the sub-Saharan African region.[2] Despite this 
expansion, there remain significant weaknesses in identification 
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Background. Identification of patients on antiretroviral therapy (ART) with virological failure (VF) and the response in the public health 
sector remain significant challenges. We previously reported improvement in routine viral load (VL) monitoring after ART commencement 
through a health system-strengthening, nurse-led ‘VL champion’ programme as part of a multidisciplinary team in three public sector 
clinics in Durban, South Africa.
Objectives. To report on the impact of the VL champion model adapted to identify, support and co-ordinate the management of individuals 
with VF on first-line ART in a setting with limited electronic-based record capacity.
Methods. We evaluated the VL champion model using a controlled before-after study design. A paper-based tool, the ‘high VL register’, was 
piloted under the supervision of the VL champion to improve data management, monitoring of counselling support, and enacting of clinical 
decisions. We abstracted chart and electronic data (TIER.net) for eligible individuals with VF in the year before and after implementation 
of the programme, and compared outcomes for individuals during these periods. Our primary outcome was successful completion of the 
VF pathway, defined as a repeat VL <1 000 copies/mL or a change to second-line ART within 6 months of VF. In a secondary analysis, we 
assessed the completion of each step in the pathway.
Results. We identified 60 and 56 individuals in the pre-intervention and post-intervention periods, respectively, with VF who met the 
inclusion criteria. Sociodemographic and clinical characteristics were similar between the periods. Repeat VL testing was completed in 
61.7% and 57.8% of individuals in these two groups, respectively. We found no difference in the proportion achieving our primary outcome 
in the pre- and post-intervention periods: 11/60 (18.3%; 95% confidence interval (CI) 9 - 28) and 15/56 (22.8%; 95% CI 15 - 38), respectively 
(p=0.28). In multivariable logistic regression models adjusted for potential confounding factors, individuals in the post-intervention period 
had a non-significant doubling of the odds of achieving the primary outcome (adjusted odds ratio 2.07; 95% CI 0.75 - 5.72). However, there 
was no difference in the rates of completion of each step along the first-line VF cascade of care.
Conclusions. This enhanced intervention to improve VF in the public sector using a paper-based data management system failed to 
achieve significant improvements in first-line VF management over the standard of care. In addition to interventions that better address 
patient-centred factors that contribute to VF, we believe that there are substantial limitations to and staffing requirements involved in the 
ongoing utilisation of a paper-based tool. A prioritisation is needed to further expand and upgrade the electronic medical record system 
with capabilities for prompting staff regarding patients with missed visits and critical laboratory results demonstrating VF.
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of patients experiencing VF and delays in appropriate switching to 
second-line ART.[3]
Prompt response to individuals failing therapy decreases the 
risk of mortality, opportunistic infections, drug resistance and 
HIV transmission.[4-6] Furthermore, management of VF is complex, 
particularly for over-burdened public sector clinics. Most guidelines 
recommend that individuals with VF undergo a complex series 
of clinical encounters. These include multiple visits for adherence 
support interventions, repeat VL testing, and visits to consider 
regimen changes to second-line antiretroviral therapy (ART). 
Notably, regimen changes to second-line ART often require approval 
from a senior clinical staff member. Moreover, individuals with 
VF represent an inherently complex patient population and often 
experience additional barriers to care.[7] These complexities lead to 
low resuppression rates and poor outcomes in patients with VF.[8-13]
Consequently, interventions to improve monitoring and 
management of individuals with VF are needed. We previously 
reported on the design of a health system-strengthening, nurse-led 
‘viral load champion’ programme as part of a multidisciplinary team 
in three public sector clinics in Durban, South Africa (SA). The 
programme achieved a significant improvement in VL testing rates 
after ART initiation,[14] but did not assess the management of patients 
after VF. Beginning in 2017, we piloted a paper-based tool, the ‘high 
VL register’, as part of the VL champion model to strengthen the 
response to VF management. We now report results of a controlled 
before-after study design of the pilot programme to assess whether it 
improved processes and clinical outcomes for PLWH with VF.
Methods
Study setting
The VL champion pilot programme was implemented at three public 
sector HIV clinics in Durban: Clairwood Hospital, Wentworth 
Hospital and King Dinizulu Hospital. Prior to the intervention in 
2017, monitoring of patients with VF was expected to be conducted 
in accordance with SA National Department of Health guidelines. [7] 
However, no specific clinic staff were delegated the tasks of identifying 
or monitoring patients with VF, which generally occurred on an ad 
hoc basis. A paper-based tool, the high VL register (available as a 
supplementary file at http://samj.org.za/public/sup/15432.pdf), was 
used in the VL champion model as part of a multidisciplinary team 
within a standard operating procedure (SOP) to monitor patient 
visits and assist in management of the VF cascade of care.
Intervention description
In January 2017, we implemented a health system-strengthening 
programme to manage VF at each of the three clinics. The programme 
included the following elements: 
• Assignment of a nurse as the ‘VL champion’ at each clinic to 
supervise the staff responsible for monitoring all patients with a 
detectable VL.
• Development of an SOP for management of VF by clinic staff. 
Training on the SOP was provided to: (i) a lay counsellor or nurse 
assigned to adherence counselling; (ii) a nurse and/or doctor 
assigned to manage the VF clinic; (iii) an administrative clerk for 
records handling; and (iv) a data clerk to ensure same-day data 
entry. In brief, VL results were reviewed daily by the VL champion 
and filed or entered in the patient charts. Patient charts with a 
high VL result were identified with a sticker and filed separately 
from the remaining clinic charts by the administrative clerk. 
Upon return to the clinic, those marked with a high VL sticker 
were identified by the administrative clerk and referred directly 
to the counsellor, who performed adherence counselling and 
then referred the patient to the high VL physician or nurse. The 
lay counsellor also managed completion of the high VL register 
(http://samj.org.za/public/sup/15432.pdf) and was expected to call 
patients who missed a clinic appointment within a week at any 
point of the follow-up period.
Study population and data sources
All adult patients on first-line ART (zidovudine or tenofovir, 
lamivudine and efavirenz) with a VL >1 000 copies/mL were screened 
for eligibility from the following data sources: TIER.net,[15] patient 
clinical charts, or the weekly clinic electronic dashboard of the National 
Health Laboratory Service. We excluded pregnant patients and those 
actively participating in other research studies in the clinic. Data were 
abstracted at the three intervention clinics during December 2015 - 
December 2017. For each participant who met the inclusion criteria, 
sociodemographic data, laboratory data (CD4 count and HIV-1 RNA 
VL), dates of clinic visits and enhanced adherence counselling (EAC) 
events, and dates of regimen changes were obtained.
Study design and statistical methods
We evaluated the VL champion intervention using a controlled 
before-after observational design. The primary exposure of interest 
was the outcomes in the cascade in the two periods, pre-intervention 
(December 2015 - December 2016) and post-intervention with the 
VL champion model (January 2017 - December 2017). Individuals 
were allocated by their first clinic visit after a VL >1 000 copies/mL 
during 2016 as being in the pre-intervention period, and those with 
their first visit after a VL >1 000 copies/mL during 2017 as being in 
the post-intervention period. Those with a VL >1 000 copies/mL and 
no additional visits were included in the analysis and categorised by 
the year of their high VL.
The primary outcome was appropriate response completed to the 
repeat VL, specifically a VL <1 000 copies/mL or change to a protease 
inhibitor-based regimen after a repeat VL >1 000 copies/mL within 
6 months of VF. Secondary outcomes included completion of at least 
one EAC session and completion of a repeat VL within 6 months.
Fisher’s exact tests and χ2 tests were used to compare descriptive 
indices of individuals in the pre- and post-intervention periods. 
Crude rates of outcomes by intervention period were estimated and 
graphically depicted the ‘second-line cascade of care’ to describe the 
proportion of people with first-line VF who successfully completed 
>1  EAC and a repeat VL, and had appropriate response completed. 
Finally, we fitted logistic regression models to identify correlates of our 
primary outcome with and without confounders, including age, sex, 
CD4 count, ART duration, ART regimen, and clinic of attendance. All 
data analyses were completed with Stata version 15.1 (StataCorp, USA).
Ethical considerations
The study protocol was approved by the KwaZulu-Natal Provincial 
Health Research Committee and the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal (ref. no. BFC 377/16).
Results
A total of 116 individuals were identified as eligible for the assess ment 
on first-line ART with a VL >1 000 copies/mL. During the observation 
period, 60 individuals (including 3 with no additional visit) were 
eligible in the pre-intervention period and 56 (including 4 with no 
additional visit) in the post-intervention period (Table 1). Participants 
in the two periods were similar in terms of sociodemographic and 
clinical characteristics. The primary outcome, confirmation of a 
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repeat VL <1 000 copies/mL or a change 
to second-line ART within 6 months, was 
similar in the pre- and post-intervention 
groups (11/60 (18.3%; 95% confidence 
interval (CI) 9 - 28) and 15/56 (26.8%; 
95% CI 15 - 38), respectively (p=0.28)). 
In multivariable logistic regression models 
adjusted for potential confounding factors, 
individuals in the post-intervention period 
had a non-significant doubling of the odds 
of achieving the primary outcome (adjusted 
odds ratio 2.07; 95% CI 0.75 - 5.72) (Table 2).
We found similar trends across the first-
line failure cascade of care (Fig. 1). In the pre- 
and post-intervention groups, 37/60 (61.7%) 
and 29/56 (51.8%) individuals, respectively, 
had a second VL done. Of those with a 
second VL result <1 000 copies/mL, only 
8.3% and 10.7%, respectively, were managed 
as per the guidelines by continuation of first-
line ART; 10.1% and 16.1%, respectively, 
were changed to second-line ART with a 
VL >1 000 copies/mL within 6 months of 
detection of VF.
Discussion
The VL champion model was developed 
to address barriers to improving routine 
VL testing and monitoring. We previously 
reported successful outcomes in improving 
VL completion rates utilising the VL 
champion model after ART initiation from 
62% to >90% at 1 year and maintaining high 
VL suppression rates.[14] We now report the 
results of adapting the VL champion model 
to use a paper-based ‘high VL register’ to 
manage the small but significant numbers of 
individuals with VF. There was no significant 
difference in the primary outcome for the 
confirmation of a repeat VL <1 000 copies/
mL or a change to second-line ART within 
6 months of detection of VF in the pre- and 
post-intervention groups. In both groups, 
poor outcomes were reported at all stages 
of the VF cascade of care (number of EAC 
sessions, second VL and subsequent visit 
after repeat VL).
This study reinforces prior work demon-
strating extremely poor outcomes after 
first- line ART failure in sub-Saharan 
Africa.[9] Potentially more concerning 
than suboptimal VL monitoring is the 
startlingly low response to a detectable VL 
that we observed in this cohort in the pre-
intervention and post-intervention periods. 
Our findings are similar to a Mozambican 
study that also reported a poor cascade of 
care in health system response to VF.[11] In 
that study, only 35% of individuals with 
detected VF had an appropriate repeat test, 
which showed 62% to have persistent VF. 
Only a third of those with persistent VF 
appropriately started second‐line ART. An 
analysis from rural KwaZulu-Natal Province 
using electronic health records also reported 
very poor management of VF.[10] Only 34% 
of patients had a VL documented 12 months 
after starting ART, and only 18% of these 
had the recommended repeat VL conducted. 
In total, and similar to our study, only 






















































Fig. 1. Second-line cascade of care before and after implementation of a nurse-led viral load monitoring and 
management programme. (EAC = enhanced adherence counselling; VL = viral load; ART = antiretroviral 
therapy; *Successful outcome defined as a repeat VL <1 000 copies/mL or a change to second-line ART 
after a repeat VL >1 000 copies/mL within 6 months of first-line ART virological failure.)
Table 1. Cohort characteristics
Characteristic Pre-intervention period (N=60) Post-intervention period (N=56) p-value
Age (years), median (IQR) 36 (23 - 41) 35 (30 - 39) 0.18
Female, n (%) 35 (58.3) 25 (44.6) 0.14
ART duration (years), median (IQR) 1.3 (0.5 - 3.2) 1.5 (0.5 - 3.3) 0.74
Viral load at failure (copies/mL), median (IQR) 19 443 (4 751 - 82 910) 16 963 (5 621 - 144 977) 0.64
Baseline CD4 count (cells/µL), median (IQR) 130 (38 - 223) 114 (28 - 193) 0.41
IQR = interquartile range; ART = antiretroviral therapy.
Table 2. Logistic regression model for correlates of a successful outcome after virological failure*
           Univariable models           Multivariable model
OR (95% CI) p-value aOR (95% CI) p-value
Age (each 10 years) 0.99 (0.91 - 1.06) 0.76 1.35 (0.78 - 2.35) 0.29
Female sex 1.81 (0.86 - 3.81) 0.12 3.59 (1.21 - 10.6) 0.02
Baseline viral load (log10 copies/mL) 0.99 (0.62 - 1.59) 0.97 0.89 (0.48 - 1.65) 0.70
Pre-post intervention 1.63 (0.67 - 3.94) 0.28 2.07 (0.75 - 5.72) 0.16
OR = odds ratio; CI = confidence interval; aOR = adjusted odds ratio.
*Defined as a repeat viral load <1 000 copies/mL or a change to second-line therapy.
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virological resuppression or a change to second-line therapy after VF, 
and those who did change therapy did so a median of 1 year after VF. 
These results show a consistently poor response to treatment failure 
in the region. Additional measures are needed to better identify, 
monitor, and ensure more effective clinical management for this 
high-risk population.
There was a drop in numbers of EAC sessions and second VLs 
done in the post-intervention period. If adherence counselling was 
not performed with sufficient expertise or if staff implementation 
of EAC was not consistent, the remainder of the intervention could 
be less effective, as reported in other studies.[16-18] The results of our 
intervention demonstrate that addressing health system factors alone 
may not be sufficient to improve VF management. We hypothesise 
that failure to demonstrate improved outcomes was the result of 
multiple factors. Attention was directed predominantly towards 
SOPs, training, and support for laboratory testing and results 
reporting. The patient-specific factors that may need to be addressed 
are transportation costs, work/clinical care trade-offs, stigma and 
mental health issues, which have all been shown to affect outcomes 
in this patient population.[19] A differentiated care model, which adds 
focus and resources to patients with VF, might serve to improve 
on-treatment HIV care in the public sector.[20,21]
Both groups had similar rates of repeated VL testing, yet the 
number who returned for follow-up management was very low. 
Although the team contacted missing patients, additional measures 
for those who could not be found were limited by funds and 
staffing time. There is no inherent capacity in paper-based tools to 
prompt clinic staff to follow up missed visits. This system requires 
manual entry for reconciliation of laboratory results, visit schedules 
and clinical reporting. Additionally, the available electronic data 
repositories used in KwaZulu-Natal are not updated in real time and 
are often not available to nursing staff. We believe that a priority 
should be to upgrade the electronic medical record system with the 
capacity to prompt staff to track patients and universalise access to 
up-to-date electronic data repositories. Efforts to advance online 
medical record systems across SA, as successfully implemented in 
Western Cape Province, may meaningfully improve patient flow and 
clinical care.[22]
Clearly, additional novel strategies are needed to more promptly 
identify and switch patients who qualify for second-line ART, 
specifically patients with advanced HIV, the group with the worst 
outcomes after treatment failure.[23,24] In addition to improving 
online medical record systems, a greater emphasis on task‐shifting 
to allow nurses to change patients to second‐line ART with approval 
from a doctor is worthy of further investigation.[25] Another strategy 
currently under investigation is incorporation of resistance testing 
into the management of VF, which may differentiate those with failure 
into adherence- and resistance‐based causes and could encourage 
clinicians to respond earlier.[26] The roll-out of dolutegravir-based 
ART as first-line therapy in the region, a regimen with a higher 
barrier to resistance and better tolerability, is also likely to change the 
relative importance of the workflow components for monitoring VF. 
It could conceivably make poor adherence rather than ART resistance 
the primary determinant of treatment failure.[27] Dolutegravir-based 
ART may further highlight the importance of adherence counselling 
in the management of VF and require further optimisation of the 
current VF monitoring and switch guidelines.[28]
Study limitations
Our study had limitations. The first was the small sample size, 
which may not have allowed sufficient power to detect a modest 
improvement in the outcome of interest. Second, as it was an 
observational study with a historical control group, there may have 
been unmeasured changes in patient characteristics or management 
that accrued over time and also had an impact on our outcomes. 
Third, it was an observational study that followed very soon after 
the establishment of a new model of care, so there may not have 
been sufficient time for full uptake of the new model to affect patient 
care outcomes. Finally, the clinics under investigation were mainly 
urban, and to make the findings of future studies generalisable, it will 
be essential to include rural clinics with different human resource 
profiles.
Conclusions
In summary, this study provides a basis for more comprehensive, 
evidence-based, clinical operational strategies that are sorely needed 
to improve VF management based on implementation science 
research. These programmes must address both health system and 
individual barriers to care and consider the complex mechanisms 
of detection, monitoring and response to VF. Until this standard of 
practice is available and reflected in programmatic guidelines, high 
rates of losses from care, delays in appropriate switching to second-
line ART, and poor outcomes among people with VF will remain 
unacceptably common in the region, and threaten the success and 
durability of global HIV treatment programmes. The VL champion 
model improves VL completion rates after ART commencement and 
may be expanded as a national public health intervention, but the 
model for improving VF requires further implementation research.
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